ARTICLE | Company News
Access Pharmaceuticals, Jiangsu Aosaikang Pharmaceutical Co. Ltd. deal
June 9, 2008 7:00 AM UTC
Access granted Jiangsu Aosaikang exclusive rights to develop and commercialize ProLindac (formerly AP5346) in China, Hong Kong, Macau and Taiwan. Jiangsu will be responsible for conducting two Phase...